ASLAN Pharmaceuticals Limited·Healthcare

Profitability This table compares Argos Therapeutics and ASLAN Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Argos Therapeutics N/A N/A N/A ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Risk and Volatility Argos Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile

Valuation and Earnings This table compares CannTrust and ASLAN Pharmaceuticals"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CannTrust $15.96 million 0.00 $7.39 million $0.07 N/A ASLAN Pharmaceuticals $12.00 million 0.10 -$44.22 million ($21.92) -0.03 CannTrust has higher revenue and earnings than ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.